Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2019 1
2020 3
2021 4
2022 6
2023 8
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: huckriede alw. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
Effect of DMARDs on the immunogenicity of vaccines.
van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E. van Sleen Y, et al. Among authors: huckriede alw. Nat Rev Rheumatol. 2023 Sep;19(9):560-575. doi: 10.1038/s41584-023-00992-8. Epub 2023 Jul 12. Nat Rev Rheumatol. 2023. PMID: 37438402 Review.
Comparison of air-liquid interface transwell and airway organoid models for human respiratory virus infection studies.
Ekanger CT, Dinesh Kumar N, Koutstaal RW, Zhou F, Beukema M, Waldock J, Jochems SP, Mulder N, van Els CACM, Engelhardt OG, Mantel N, Buno KP, Brokstad KA, Engelsen AST, Cox RJ, Melgert BN, Huckriede ALW, van Kasteren PB. Ekanger CT, et al. Among authors: huckriede alw. Front Immunol. 2025 Feb 6;16:1532144. doi: 10.3389/fimmu.2025.1532144. eCollection 2025. Front Immunol. 2025. PMID: 39981254 Free PMC article.
Advances in the development of entry inhibitors for sialic-acid-targeting viruses.
Heida R, Bhide YC, Gasbarri M, Kocabiyik Ö, Stellacci F, Huckriede ALW, Hinrichs WLJ, Frijlink HW. Heida R, et al. Among authors: huckriede alw. Drug Discov Today. 2021 Jan;26(1):122-137. doi: 10.1016/j.drudis.2020.10.009. Epub 2020 Oct 21. Drug Discov Today. 2021. PMID: 33099021 Free PMC article. Review.
[A preview of COVID-19 vaccination and treatment].
de Boer MGJ, Bonten MJM, Huckriede ALW. de Boer MGJ, et al. Among authors: huckriede alw. Ned Tijdschr Geneeskd. 2022 May 12;166:D6880. Ned Tijdschr Geneeskd. 2022. PMID: 36036707 Dutch.
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH; SWITCH Research Group. Sablerolles RSG, et al. Among authors: huckriede alw. Clin Infect Dis. 2023 Feb 8;76(3):e533-e536. doi: 10.1093/cid/ciac495. Clin Infect Dis. 2023. PMID: 35723273 Free PMC article.
COVID-19 vaccination: the VOICE for patients with cancer.
van der Veldt AAM, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M, Rimmelzwaan GF, Kvistborg P, Blank CU, Smit EF, Lemmens VEEP, Hiltermann TJN, Koopmans MPG, Huckriede ALW, Rots NY, van Els CACM, van Baarle D, Haanen JBAG, de Vries EGE. van der Veldt AAM, et al. Among authors: huckriede alw. Nat Med. 2021 Apr;27(4):568-569. doi: 10.1038/s41591-021-01240-w. Nat Med. 2021. PMID: 33589821 No abstract available.
Development of an inhalable antiviral powder formulation against respiratory syncytial virus.
Heida R, Akkerman R, Jacob Silva PH, Lakerveld AJ, Ortiz D, Bigogno C, Gasbarri M, van Kasteren PB, Stellacci F, Frijlink HW, Huckriede ALW, Hinrichs WLJ. Heida R, et al. Among authors: huckriede alw. J Control Release. 2023 May;357:264-273. doi: 10.1016/j.jconrel.2023.03.059. Epub 2023 Apr 5. J Control Release. 2023. PMID: 37015293 Free article.
27 results